BB-1701

DB17443InvestigationalProtein Based Therapies

BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Also known as: Humanized IgG1kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin
Code names: BB-1701

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with BB-1701, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.